SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more than 200 recent and on-going clinical trials of Celgene products including REVLIMID®, VIDAZA®, THALOMID®, pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting and Exposition from December 5-8, 2009 in New Orleans, Louisiana.
